Gastric cancer is one of the most commonly occurring cancers worldwide, often presenting at an advanced stage. Combining targeted therapy with chemotherapeutic agents can enhance and extend the survival of these patients. This 4-year retrospective study aims to assess the prognostic role of Her2-Neu expression in gastric and gastroesophageal (GE) cancer. Clinicopathological features, histological type (Lauren classification) of adenocarcinoma, and Her2 immunohistochemical expression were correlated with disease-free and overall survival in 114 patients. A Her2 score of 0 and 1+ indicated negativity, while 3+ marked positivity. For cases with a 2+ score, fluorescent in situ hybridization (FISH) was conducted for definitive categorization. Statistical analysis employed IBM SPSS version 20.0 software. Among 114 patients, 13 displayed strong Her2-Neu immunopositivity (3 + ), 9 scored 2 + , and 92 were negative (0 [89] and 1+ [3]). FISH classified 4 and 5 cases as positive and negative, respectively. Most (64.7%) Her2-Neu-positive tumors occurred in the proximal stomach/GE junction (GEJ) and exhibited intestinal morphology (94.1%) with moderate differentiation (p-value < 0.05). Notably, 76.5% of Her2-Neu-positive patients exhibited advanced-stage disease with nodal/distant metastasis. The average disease-free survival was 15.4 months (standard error: 3.55) for positive Her2-Neu expression and 22.07 months (standard error: 1.364) for negative expression. The mean overall survival was 21.14 months (standard error: 3.702) for positive expression and 23.91 months (standard error: 1.474) for negative expression. Her2-Neu expression in gastric/GEJ adenocarcinomas correlates with reduced survival. Evaluating Her2-Neu in proximal gastric/GEJ cancers displaying low-grade intestinal morphology serves as both a predictive and prognostic indicator.
{"title":"Expression of Her2-Neu in Primary Gastric and Gastroesophageal Adenocarcinoma: An Experience from a Tertiary Center in South India","authors":"Aditi Damle, Roopa Rachel Paulose, Divya Saikumar, Divya Ail, Niveditha Kartha, Renjitha Bhaskaran, Wesley Jose, Vidhya Jha","doi":"10.1055/s-0043-1774290","DOIUrl":"https://doi.org/10.1055/s-0043-1774290","url":null,"abstract":"Gastric cancer is one of the most commonly occurring cancers worldwide, often presenting at an advanced stage. Combining targeted therapy with chemotherapeutic agents can enhance and extend the survival of these patients. This 4-year retrospective study aims to assess the prognostic role of Her2-Neu expression in gastric and gastroesophageal (GE) cancer. Clinicopathological features, histological type (Lauren classification) of adenocarcinoma, and Her2 immunohistochemical expression were correlated with disease-free and overall survival in 114 patients. A Her2 score of 0 and 1+ indicated negativity, while 3+ marked positivity. For cases with a 2+ score, fluorescent in situ hybridization (FISH) was conducted for definitive categorization. Statistical analysis employed IBM SPSS version 20.0 software. Among 114 patients, 13 displayed strong Her2-Neu immunopositivity (3 + ), 9 scored 2 + , and 92 were negative (0 [89] and 1+ [3]). FISH classified 4 and 5 cases as positive and negative, respectively. Most (64.7%) Her2-Neu-positive tumors occurred in the proximal stomach/GE junction (GEJ) and exhibited intestinal morphology (94.1%) with moderate differentiation (p-value < 0.05). Notably, 76.5% of Her2-Neu-positive patients exhibited advanced-stage disease with nodal/distant metastasis. The average disease-free survival was 15.4 months (standard error: 3.55) for positive Her2-Neu expression and 22.07 months (standard error: 1.364) for negative expression. The mean overall survival was 21.14 months (standard error: 3.702) for positive expression and 23.91 months (standard error: 1.474) for negative expression. Her2-Neu expression in gastric/GEJ adenocarcinomas correlates with reduced survival. Evaluating Her2-Neu in proximal gastric/GEJ cancers displaying low-grade intestinal morphology serves as both a predictive and prognostic indicator.","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135534794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Haploidentical transplant (haploSCT) has its own unique complications; hence, we studied the outcome of haploSCT from a cancer hospital in India. We retrospectively analyzed the haploSCTs performed at our center between March 2015 and mid-August 2022 using posttransplant cyclophosphamide (PTCy). Ninety-nine patients (95 malignant and 4 nonmalignant) underwent 101 haploSCTs. Myeloablative (MA), nonmyeloablative (NMA), and reduced intensity conditioning (RIC) were used in 35 (34.6%), 43 (42.5%), and 23 (22.7%) transplants, respectively. The median CD34 + was 5.9 (1.8–10) ×106/kg. The median time to neutrophil and platelet engraftment was 15 (11–32) and 15.5 (9–120) days, respectively. There were 09 (8.9%) cases of primary graft rejection. Eighteen (17.8%) patients had a relapse. Acute graft versus host disease (GVHD) was observed in 33 (32.6%) cases. Blood cultures were positive in 42 (41.5%) transplants. Common viral infections were BK (47.3%) and cytomegalovirus (CMV; 65.3%). The median follow-up was 6 (0.5–89.5) months. Forty-eight (48.4%) patients had died at the last follow-up. The main causes of the death were sepsis (27 [56.2%]), relapse (10 [22.2%]), and GVHD (04 [8.8%]). The nonrelapse mortality was 37.3%. The median overall survival (OS) was 18 ± 11.46 (0–40.77) months. The 1-year OS was 56.7%, while the 2-year OS was 49.3%. We emphasize that haploSCT offers a reasonable hope of survival for patients, although infections remain a significant challenge based on our experience.
{"title":"Haploidentical Stem Cell Transplantation for Hematological Disorders: Real-World Experience from India","authors":"Pallavi Mehta, Vishvdeep Khushoo","doi":"10.1055/s-0043-1771274","DOIUrl":"https://doi.org/10.1055/s-0043-1771274","url":null,"abstract":"Haploidentical transplant (haploSCT) has its own unique complications; hence, we studied the outcome of haploSCT from a cancer hospital in India. We retrospectively analyzed the haploSCTs performed at our center between March 2015 and mid-August 2022 using posttransplant cyclophosphamide (PTCy). Ninety-nine patients (95 malignant and 4 nonmalignant) underwent 101 haploSCTs. Myeloablative (MA), nonmyeloablative (NMA), and reduced intensity conditioning (RIC) were used in 35 (34.6%), 43 (42.5%), and 23 (22.7%) transplants, respectively. The median CD34 + was 5.9 (1.8–10) ×106/kg. The median time to neutrophil and platelet engraftment was 15 (11–32) and 15.5 (9–120) days, respectively. There were 09 (8.9%) cases of primary graft rejection. Eighteen (17.8%) patients had a relapse. Acute graft versus host disease (GVHD) was observed in 33 (32.6%) cases. Blood cultures were positive in 42 (41.5%) transplants. Common viral infections were BK (47.3%) and cytomegalovirus (CMV; 65.3%). The median follow-up was 6 (0.5–89.5) months. Forty-eight (48.4%) patients had died at the last follow-up. The main causes of the death were sepsis (27 [56.2%]), relapse (10 [22.2%]), and GVHD (04 [8.8%]). The nonrelapse mortality was 37.3%. The median overall survival (OS) was 18 ± 11.46 (0–40.77) months. The 1-year OS was 56.7%, while the 2-year OS was 49.3%. We emphasize that haploSCT offers a reasonable hope of survival for patients, although infections remain a significant challenge based on our experience.","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135478790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vikas Maheshwari, Mohit Dhingra, Divyansh Sharma, Aditya K. S. Gowda, Arun Kurmi, Surabhi Das
Bone bank has become an essential requirement for centers that perform tumor and reconstructive surgeries. It provides allogenic bone procured from cadavers as well as live donors in the form of surgical residues. Thus, we conducted a retrospective observational study on recipients who underwent various reconstructive procedures using fresh frozen allograft obtsined from the live donors through surgical residues in a newly established bone bank. The outcomes of cases operated where allogenic bone grafts were used between January 2018 and November 2020 were analyzed in terms of infection and time taken for the grafts to incorporate, allowing weight-bearing in the lower limbs. A total of 223 grafts were obtained as surgical residues from replacement surgeries and traumatic amputations performed on non-salvageable limbs. Out of these, 70 grafts were transplanted into eligible recipients, who were followed up for at least one year. Among the 70 recipients, 15 were lost to follow-up. The outcome data of the remaining 55 recipients was tabulated, including infections (early, delayed and late) and the achievement of weight-bearing milestones when transplanted in lower limbs. Out of the 55 cases, allografts were used alone in 20 cases, while in 35 cases, they were augmented by implants or cement. Two cases (3.6%) experienced acute infections, and another two cases (3.6%) had chronic infection. The mean time for weight-bearing was found to be 7 months when used alone and 3.5 months when augmented with cement or an implant. Additionally, five patients did not show complete integration of the graft. The results of using allogenic bone graft are quite encouraging, suggesting their potential as biological adjuvants in reconstructive surgeries.
{"title":"Retrospective Outcome Analysis of Allogenic Bone Graft","authors":"Vikas Maheshwari, Mohit Dhingra, Divyansh Sharma, Aditya K. S. Gowda, Arun Kurmi, Surabhi Das","doi":"10.1055/s-0043-1772775","DOIUrl":"https://doi.org/10.1055/s-0043-1772775","url":null,"abstract":"Bone bank has become an essential requirement for centers that perform tumor and reconstructive surgeries. It provides allogenic bone procured from cadavers as well as live donors in the form of surgical residues. Thus, we conducted a retrospective observational study on recipients who underwent various reconstructive procedures using fresh frozen allograft obtsined from the live donors through surgical residues in a newly established bone bank. The outcomes of cases operated where allogenic bone grafts were used between January 2018 and November 2020 were analyzed in terms of infection and time taken for the grafts to incorporate, allowing weight-bearing in the lower limbs. A total of 223 grafts were obtained as surgical residues from replacement surgeries and traumatic amputations performed on non-salvageable limbs. Out of these, 70 grafts were transplanted into eligible recipients, who were followed up for at least one year. Among the 70 recipients, 15 were lost to follow-up. The outcome data of the remaining 55 recipients was tabulated, including infections (early, delayed and late) and the achievement of weight-bearing milestones when transplanted in lower limbs. Out of the 55 cases, allografts were used alone in 20 cases, while in 35 cases, they were augmented by implants or cement. Two cases (3.6%) experienced acute infections, and another two cases (3.6%) had chronic infection. The mean time for weight-bearing was found to be 7 months when used alone and 3.5 months when augmented with cement or an implant. Additionally, five patients did not show complete integration of the graft. The results of using allogenic bone graft are quite encouraging, suggesting their potential as biological adjuvants in reconstructive surgeries.","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"115 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135534544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-15eCollection Date: 2023-04-01DOI: 10.1055/s-0043-1772678
Purvish M Parikh
Purvish M. ParikhWe describe the facts of the matter and the court's decision in a case of an Ayurveda, Yoga & Naturopathy, Unani, Siddha, and Homeopathy (AYUSH) doctor being found guilty of deficiency of service by prescribing allopathic medicines that were associated with known complications. The case details include the allegation, the defense, and the court's judgement. Details of the concerned acts, circulars, and regulations, as well as court case laws, are described. The regulations allow AYUSH doctors to prescribe allopathic medicines under certain circumstances, which were not adhered to in this case.
Purvish M. ParikhWe描述了一名阿育吠陀、瑜伽和自然疗法、乌纳尼、悉达和顺势疗法(AYUSH)医生因开出与已知并发症相关的对抗疗法药物而被判犯有服务不足罪的案件的事实和法院的裁决。案件细节包括指控、辩护和法院判决。详细介绍了有关的法令、通告和规章，以及法院判例法。条例允许AYUSH医生在某些情况下开对症药物，但在本案中没有遵守。
{"title":"Ayurvedic Doctors Cannot Prescribe Allopathic Medicines-National Consumer Dispute Redressal Commission Judgement.","authors":"Purvish M Parikh","doi":"10.1055/s-0043-1772678","DOIUrl":"https://doi.org/10.1055/s-0043-1772678","url":null,"abstract":"<p><p>Purvish M. ParikhWe describe the facts of the matter and the court's decision in a case of an Ayurveda, Yoga & Naturopathy, Unani, Siddha, and Homeopathy (AYUSH) doctor being found guilty of deficiency of service by prescribing allopathic medicines that were associated with known complications. The case details include the allegation, the defense, and the court's judgement. Details of the concerned acts, circulars, and regulations, as well as court case laws, are described. The regulations allow AYUSH doctors to prescribe allopathic medicines under certain circumstances, which were not adhered to in this case.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"12 2","pages":"100-103"},"PeriodicalIF":0.5,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134649761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-15eCollection Date: 2023-04-01DOI: 10.1055/s-0043-1771445
Purvish Mahendra Parikh, Shyam Aggarwal, Ghanashyam Biswas, Seema Gulia, Vivek Agarwala, Maheboob Basade, P N Mohapatra, Krishna Muddu Vamshi, Arun Warrier, Krishna Prasad, Partha Roy, M V Chandrakant, Hemant Malhotra, Sachin Hingmire, Davinder Paul, Vashista Maniar, Alok Gupta, Soumya S Panda, Aseem Samar, Nitesh Rohatgi, Satya Dattatreya, Manjunath Krishnamurthy, Raja Thirumalairaj
Purvish M. ParikhCancer-associated anemia (CAA) remains a major unmet need that compromises overall survival (OS) and quality of life (QoL). Currently, available guidelines do not take into consideration the unique challenges in low- and middle-income countries (LMIC). Our CAA patients have to battle preexisting impaired nutritional status, depleted body iron stores, financial limitations, and difficulty in having easily accessible affordable healthcare. Hence, we fulfilled the need of guidelines for LMIC. A group of subject experts were put together, given background literature, met in a face-to-face discussion, voted using Delphi process, and finally agreed on the contents of this guideline document. As many as 50% of cancer patients will have significant anemia (hemoglobin < 10 g/dL) at initial diagnosis. It is most commonly seen with gastrointestinal malignancies, head and neck cancers, and acute leukemias. The hemoglobin falls further after initiation of cancer directed therapy, due to chemotherapy itself or heightened nutritional deficiency. Its evaluation should include tests for complete blood count, red blood cell morphology, reticulocyte count, Coombs test, and levels of vitamin B12 and folic acid. Iron status should be monitored using test to measure serum iron, total iron binding capacity, transferring saturation, and serum ferritin levels. A minimum of 50% of cancer patients with anemia require iron supplements. The preferred mode of therapy is with intravenous (IV) iron using ferric carboxymaltose (FCM). Most patients respond satisfactorily to single dose of 1000 mg. It is also safe and does not require use of a test dose. Significant anemia is found in at least half of all cancer patients in India, South Asian Association for Regional Cooperation region, and other LMIC countries. Its awareness among healthcare professionals will prevent it from remaining undiagnosed (in up to 70% of all cancer patients) and adversely affecting OS and QoL. The benefits of treating them with IV iron therapy are quick replenishment of iron stores, hemoglobin returning to normal, better QoL, and avoiding risk of infections/reactions with blood transfusions. Many publications have proven the value of single-dose FCM in such clinical situations. CAA has been proven to be an independent prognostic factor that adversely affects both QoL and OS in cancer patients. Use of FCM as single IV dose of 1000 mg is safe and effective in the majority of patients with CAA.
{"title":"Practical Clinical Consensus Guidelines for the Management of Cancer Associated Anemia in Low- and Middle-Income Countries.","authors":"Purvish Mahendra Parikh, Shyam Aggarwal, Ghanashyam Biswas, Seema Gulia, Vivek Agarwala, Maheboob Basade, P N Mohapatra, Krishna Muddu Vamshi, Arun Warrier, Krishna Prasad, Partha Roy, M V Chandrakant, Hemant Malhotra, Sachin Hingmire, Davinder Paul, Vashista Maniar, Alok Gupta, Soumya S Panda, Aseem Samar, Nitesh Rohatgi, Satya Dattatreya, Manjunath Krishnamurthy, Raja Thirumalairaj","doi":"10.1055/s-0043-1771445","DOIUrl":"10.1055/s-0043-1771445","url":null,"abstract":"<p><p>Purvish M. ParikhCancer-associated anemia (CAA) remains a major unmet need that compromises overall survival (OS) and quality of life (QoL). Currently, available guidelines do not take into consideration the unique challenges in low- and middle-income countries (LMIC). Our CAA patients have to battle preexisting impaired nutritional status, depleted body iron stores, financial limitations, and difficulty in having easily accessible affordable healthcare. Hence, we fulfilled the need of guidelines for LMIC. A group of subject experts were put together, given background literature, met in a face-to-face discussion, voted using Delphi process, and finally agreed on the contents of this guideline document. As many as 50% of cancer patients will have significant anemia (hemoglobin < 10 g/dL) at initial diagnosis. It is most commonly seen with gastrointestinal malignancies, head and neck cancers, and acute leukemias. The hemoglobin falls further after initiation of cancer directed therapy, due to chemotherapy itself or heightened nutritional deficiency. Its evaluation should include tests for complete blood count, red blood cell morphology, reticulocyte count, Coombs test, and levels of vitamin B12 and folic acid. Iron status should be monitored using test to measure serum iron, total iron binding capacity, transferring saturation, and serum ferritin levels. A minimum of 50% of cancer patients with anemia require iron supplements. The preferred mode of therapy is with intravenous (IV) iron using ferric carboxymaltose (FCM). Most patients respond satisfactorily to single dose of 1000 mg. It is also safe and does not require use of a test dose. Significant anemia is found in at least half of all cancer patients in India, South Asian Association for Regional Cooperation region, and other LMIC countries. Its awareness among healthcare professionals will prevent it from remaining undiagnosed (in up to 70% of all cancer patients) and adversely affecting OS and QoL. The benefits of treating them with IV iron therapy are quick replenishment of iron stores, hemoglobin returning to normal, better QoL, and avoiding risk of infections/reactions with blood transfusions. Many publications have proven the value of single-dose FCM in such clinical situations. CAA has been proven to be an independent prognostic factor that adversely affects both QoL and OS in cancer patients. Use of FCM as single IV dose of 1000 mg is safe and effective in the majority of patients with CAA.</p>","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"12 2","pages":"93-99"},"PeriodicalIF":0.6,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134649762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
No studies have examined the impact of human papillomavirus (HPV)-16 and HPV-18 on survival, inflammation biomarkers, and immune function in early-stage cervical cancer patients undergoing surgery. Patients diagnosed with early-stage cervical cancer were screened for high-risk HPV prior to surgery. The influence of HPV infection on survival, inflammatory markers, and immune function was investigated. Findings revealed that patients in the HPV-18 positive subgroup exhibited poorer disease-free survival (DFS) and elevated levels of interleukin-6 and C-reactive protein, along with decreased CD4+ T cells compared to patients who tested negative for HPV-18. Notably, early-stage cervical cancer patients with HPV-18 infection experienced worse DFS, heightened inflammatory markers, and compromised immune function.
{"title":"Impact of Human Papillomavirus on Survival, Inflammation, and Immune Function in Patients with Cervical Cancer Undergoing Surgery","authors":"Hui Hua, Xiaoyong Lei, Jia Yu, Xinxin Zhang","doi":"10.1055/s-0043-1774709","DOIUrl":"https://doi.org/10.1055/s-0043-1774709","url":null,"abstract":"No studies have examined the impact of human papillomavirus (HPV)-16 and HPV-18 on survival, inflammation biomarkers, and immune function in early-stage cervical cancer patients undergoing surgery. Patients diagnosed with early-stage cervical cancer were screened for high-risk HPV prior to surgery. The influence of HPV infection on survival, inflammatory markers, and immune function was investigated. Findings revealed that patients in the HPV-18 positive subgroup exhibited poorer disease-free survival (DFS) and elevated levels of interleukin-6 and C-reactive protein, along with decreased CD4+ T cells compared to patients who tested negative for HPV-18. Notably, early-stage cervical cancer patients with HPV-18 infection experienced worse DFS, heightened inflammatory markers, and compromised immune function.","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135825918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The aim of this study was to translate and validate the European Organization for Research and Treatment for Cancer (EORTC) “Radiation Proctitis” (PRT-20) module in Hindi, Marathi, and Bangla languages. The EORTC PRT-20 was translated into Hindi, Marathi, and Bangla using EORTC guidelines. Two separate translators first translated the original questionnaire into the three regional languages, following which a reconciled forward translation was compiled. This reconciled version in each language was then back-translated into English by two other translators. This back-translated version was then compared with the original the EORTC questionnaire for correctness, and the preliminary questionnaires were formed in all three languages. The EORTC translation unit approved the questionnaires. The preliminary questionnaires were administered to 30 patients (10 for each language) diagnosed with rectal or anal canal cancer who had received pelvic radiotherapy and were at risk of developing PRT. None of the patients had seen the questionnaire before. After filling out the questionnaire, each patient was interviewed for difficulty in answering, confusion, understanding, or if any of the questions were upsetting and if patients would have asked the question differently. No changes were suggested for Marathi and Bangla translations. Two modifications were suggested in the Hindi translation, which was then retested in five patients and finalized. All the suggestions were incorporated into the preliminary questionnaires, which were sent back to the EORTC for final approval. After reviewing the entire report of pilot testing for the translated quality-of-life questionaire-PRT-20 in three languages, it was approved by the EORTC translation unit. The translated questionnaires were reliable, with Cronbach α values of 0.767, 0.799, and 0.898 for Hindi, Marathi, and Bangla, respectively. The Hindi, Marathi, and Bangla translations of PRT-20 have been approved by the EORTC and can be used in routine clinical practice.
{"title":"Translation and Pilot Validation of Hindi, Marathi, and Bangla Translation of Quality-of-Life EORTC Radiation Proctitis Module (PRT-20) for Routine Clinical Use","authors":"Revathy Krishnamurthy, Rahul Krishnatry, Devankshi Rane, Purva Pawar, Debanjan Chakraborty, Utpal Gaikwad, Suman Ghosh, Aasma Siddiqui, Debanjali Datta, Akanksha Anup, Sayan Das, Shivakumar Gudi, Reena Engineer","doi":"10.1055/s-0043-1771442","DOIUrl":"https://doi.org/10.1055/s-0043-1771442","url":null,"abstract":"The aim of this study was to translate and validate the European Organization for Research and Treatment for Cancer (EORTC) “Radiation Proctitis” (PRT-20) module in Hindi, Marathi, and Bangla languages. The EORTC PRT-20 was translated into Hindi, Marathi, and Bangla using EORTC guidelines. Two separate translators first translated the original questionnaire into the three regional languages, following which a reconciled forward translation was compiled. This reconciled version in each language was then back-translated into English by two other translators. This back-translated version was then compared with the original the EORTC questionnaire for correctness, and the preliminary questionnaires were formed in all three languages. The EORTC translation unit approved the questionnaires. The preliminary questionnaires were administered to 30 patients (10 for each language) diagnosed with rectal or anal canal cancer who had received pelvic radiotherapy and were at risk of developing PRT. None of the patients had seen the questionnaire before. After filling out the questionnaire, each patient was interviewed for difficulty in answering, confusion, understanding, or if any of the questions were upsetting and if patients would have asked the question differently. No changes were suggested for Marathi and Bangla translations. Two modifications were suggested in the Hindi translation, which was then retested in five patients and finalized. All the suggestions were incorporated into the preliminary questionnaires, which were sent back to the EORTC for final approval. After reviewing the entire report of pilot testing for the translated quality-of-life questionaire-PRT-20 in three languages, it was approved by the EORTC translation unit. The translated questionnaires were reliable, with Cronbach α values of 0.767, 0.799, and 0.898 for Hindi, Marathi, and Bangla, respectively. The Hindi, Marathi, and Bangla translations of PRT-20 have been approved by the EORTC and can be used in routine clinical practice.","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135878278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Diksha Dinker, A. Pai, Keshava Rajan, Naveena A. N. Kumar
Abstract Naveena A.N. Kumar A high incidence of locoregional recurrences in oral cavity cancers remains the biggest challenge leading to treatment failures post-surgery and radiotherapy. Our case report elaborates on one such recurrence pattern and the juxtaposition of various modalities applied to successfully not only eradicate the tumor but also to keep the recurrence at bay.
{"title":"Successful Treatment of Recurrent Unresectable Oral Cancer with Sequential Targeted Therapy, Surgery, and Metronomic Chemotherapy","authors":"Diksha Dinker, A. Pai, Keshava Rajan, Naveena A. N. Kumar","doi":"10.1055/s-0043-1773793","DOIUrl":"https://doi.org/10.1055/s-0043-1773793","url":null,"abstract":"Abstract Naveena A.N. Kumar A high incidence of locoregional recurrences in oral cavity cancers remains the biggest challenge leading to treatment failures post-surgery and radiotherapy. Our case report elaborates on one such recurrence pattern and the juxtaposition of various modalities applied to successfully not only eradicate the tumor but also to keep the recurrence at bay.","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48473765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-31eCollection Date: 2023-07-01DOI: 10.1055/s-0043-1773794
Venkata Pradeep Babu Koyyala
{"title":"On the Other Side of the Table.","authors":"Venkata Pradeep Babu Koyyala","doi":"10.1055/s-0043-1773794","DOIUrl":"10.1055/s-0043-1773794","url":null,"abstract":"","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":"1 1","pages":"309-310"},"PeriodicalIF":0.5,"publicationDate":"2023-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10691902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41434424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Jaiswal, Aastha Gupta, M. Dixit, Govind R. Patel, S. Mohanty
Abstract Aastha Gupta We describe diagnostic and therapeutic challenges in this rare entity of CD20-negative B cell lymphomas. They comprise only 1 to 2% of all B cell lymphoma with four subcategories. However, with an increasing understanding of these cases, novel entities have been recognized. Workup, treatment, and follow-up of two CD20-negative B cell lymphoma cases, including a novel entity, have been described. A novel case of triple expresser CD20-negative B cell lymphoma and plasmablastic lymphoma has been diagnosed. The absence of CD20 leads to the abolishment of the targeted drug (rituximab) from the treatment regimen. These cases render the importance of extensive immunohistochemistry and fluorescence in situ hybridization workup for diagnosis of this rare entity. Treatment also remains a challenge as immunotherapy with CD20-targeted drugs cannot be given.
{"title":"CD20-Negative Primary Bone Marrow Large B Cell Lymphoma: A Report of Two Cases with Review of Literature","authors":"A. Jaiswal, Aastha Gupta, M. Dixit, Govind R. Patel, S. Mohanty","doi":"10.1055/s-0043-1768707","DOIUrl":"https://doi.org/10.1055/s-0043-1768707","url":null,"abstract":"Abstract Aastha Gupta We describe diagnostic and therapeutic challenges in this rare entity of CD20-negative B cell lymphomas. They comprise only 1 to 2% of all B cell lymphoma with four subcategories. However, with an increasing understanding of these cases, novel entities have been recognized. Workup, treatment, and follow-up of two CD20-negative B cell lymphoma cases, including a novel entity, have been described. A novel case of triple expresser CD20-negative B cell lymphoma and plasmablastic lymphoma has been diagnosed. The absence of CD20 leads to the abolishment of the targeted drug (rituximab) from the treatment regimen. These cases render the importance of extensive immunohistochemistry and fluorescence in situ hybridization workup for diagnosis of this rare entity. Treatment also remains a challenge as immunotherapy with CD20-targeted drugs cannot be given.","PeriodicalId":22053,"journal":{"name":"South Asian Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":0.5,"publicationDate":"2023-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48064464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：